Building strength, one steady rep at a time

Neutral report

Sales in-line, EBIT +1% vs cons. Cons estm relatively unchanged, stock up 1-2%

Telia Company AB: 1 director

A director at Telia Company AB bought 35,000 shares at 35.020SEK and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

On track for scalable growth

Q2: Solid report

EU Telecoms: Half-time 2025 Review Sector has outperformed: More sele...

The European Telecoms continues to outperform: up 17% YTD vs. the market up 10%. While this is great to see, adding to the 12pp outperformance in 2024 and supporting our investment thesis of improving regulation, it does mean the equity upside story from here is becoming more selective.

Telia performs well/Bredband2 acquisition doesn't come cheap

Telia reported solid 2Q25 results which were in line with expectations. However, the most interesting news was its bid for Bredband2, a large Swedish provider of broadband services. Although we think the intended acquisition comes somewhat expensive, we like the potential improvement of Telia's broadband market share to c.41.5% in Sweden. Regulatory approval for the transaction is very well possible when comparing Sweden with other European countries. Telia's credit profile continues to look sou...

Telia (Buy from Neutral, TP: SEK 40, +15%) OpEx execution (& M&A) lif...

It has been a busy few days for Telia: it reported a good set of Q2 results last week and announced a deal to sell its Latvian business and a deal to buy Swedish fibre provider Bredband2. We look at these events in this report, and upgrade Telia to a Buy.

Not enough to excite us

Small cost driven beat

Q2e: near-term ARPU drag, earnings on track

Headwinds entering in Q2e

Trends continue, valuation not too appealing

Q2 slightly off the mark

Expert speaker call: latent market share gains

New targets fulfilling our wish list

Sats (Hold, TP: NOK37.00) - Time for a breather

Q1 was slightly below expectations and the CMD targets were broadly in line with our forecasts and consensus. We have raised our target price to NOK37 (34) on higher estimates but have downgraded to HOLD (BUY), as we find the valuation fair following the recent strong share price performance.

Sweden needed for a homerun

Lundbeck (Buy, TP: DKK48.00) - Focus on Vyepti sales

We forecast Q1 sales c0.5% above consensus and an adj. EBITDA margin of 31.3%. We expect the strategic brands sales to rise by 18.3% YOY, including Vyepti sales of DKK913m (c2.2% above consensus). We forecast unchanged 2025 guidance for CER figures. From the pipeline, the FDA AdCom for Rexulti in PTSD is still unscheduled and the PROCEED trial has recently been expanded to additional IV doses. We reiterate our BUY, but have cut our target price to 48 (56).

EBIT 4% below, strong growth expected

EBIT 4% below on 4% higher cost. Members strong, +2% vs cons. Targets EPS of over NOK 3